Athena Athena

X
[{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Protagenic Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).

            Lead Product(s): PT00114

            Therapeutic Area: Psychiatry/Psychology Product Name: PT00114

            Highest Development Status: IND Enabling Product Type: Peptide

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Financing September 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY